Publications for Leslie Citrome nntman@gmail.com
Citrome, L. (2016). Aripiprazole long-acting injectable formulations for schizophrenia: Aripiprazole monohydrate and aripiprazole lauroxil. Expert Review of Clinical Pharmacology, 9(2), 169-186. doi:10.1586/17512433.2016.1121809
Citrome, L. (2016). Breakthrough drugs for the interface between psychiatry and neurology. International Journal of Clinical Practice, 70(4), 298-299. doi:10.1111/ijcp.12805
Citrome, L. (2016). Cariprazine for the treatment of schizophrenia: A review of this dopamine D3-preferring D3/D2 receptor partial agonist. Clinical Schizophrenia & Related Psychoses, 10(2), 109-119. doi:10.3371/1935-1232-10.2.109
Citrome, L. (2016). Emerging pharmacological therapies in schizophrenia: What's new, what's different, what's next? CNS Spectrums, 21(S1), 1-12. doi:10.1017/S1092852916000729
Citrome, L. (2016). Food for thought: Do you ask about eating? International Journal of Clinical Practice, 70(7), 516-517. doi:10.1111/ijcp.12845
Citrome, L. (2016). From banknotes to people: One million is impressive. International Journal of Clinical Practice, 70(9), 702-703. doi:10.1111/ijcp.12875
Citrome, L. (2016). How do I get my manuscript accepted? Steps and missteps. International Journal of Clinical Practice, 70(2), 97-98. doi:10.1111/ijcp.12782
Citrome, L. (2016). More food for thought: Preferred words. International Journal of Clinical Practice, 70(8), 640. doi:10.1111/ijcp.12865
Citrome, L. (2016). Open researcher and contributor ID: ORCID now mandatory for Wiley journals. International Journal of Clinical Practice, 70(11), 884-885. doi:10.1111/ijcp.12912
Citrome, L. (2016). Peer review and Publons - enhancements for the reviewer. International Journal of Clinical Practice, 70(5), 364. doi:10.1111/ijcp.12827
Citrome, L. (2016). Perceptions matter: Attitudes and health outcomes. International Journal of Clinical Practice, 70(12), 966. doi:10.1111/ijcp.12923
Citrome, L. (2016). Rosacea and dementia: Relative vs. absolute effect sizes. International Journal of Clinical Practice, 70(6), 428-429. doi:10.1111/ijcp.12834
Citrome, L. (2016). Schizophrenia relapse, patient considerations, and potential role of lurasidone. Patient Preference and Adherence, 10, 1529-1537. doi:10.2147/PPA.S45401
Citrome, L. (2016). The grey literature is far from drab. International Journal of Clinical Practice, 70(10), 790. doi:10.1111/ijcp.12899
Citrome, L. (2016). Vortioxetine for major depressive disorder: An indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed. Journal of Affective Disorders, 196, 225-233. doi:10.1016/j.jad.2016.02.042
Citrome, L. (2016). What's in a name? Use of brand vs. generic drug names. International Journal of Clinical Practice, 70(1), 3-4. doi:10.1111/ijcp.12772
Citrome, L. (2016). Which role for brexpiprazole, a new dopamine D2 partial agonist, in the treatment of schizophrenia? Evidence-Based Mental Health, 19(2), e6. doi:10.1136/eb-2015-102143
Citrome, L. (2016). Zika and you. International Journal of Clinical Practice, 70(3), 181-182. doi:10.1111/ijcp.12793
Citrome, L., & Ketter, T. A. (2016). NNT and NNH remain helpful in evidence-based medicine. The British Journal of Psychiatry, 209(3), 262-263. doi:10.1192/bjp.209.3.262b
Citrome, L., Du, Y., Risinger, R., Stankovic, S., Claxton, A., Zummo, J., . . . Ehrich, E. W. (2016). Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia. International Clinical Psychopharmacology, 31(2), 69-75. doi:10.1097/YIC.0000000000000106
Citrome, L., Durgam, S., Lu, K., Ferguson, P., & Laszlovszky, I. (2016). The effect of cariprazine on hostility associated with schizophrenia: Post hoc analyses from 3 randomized controlled trials. The Journal of Clinical Psychiatry, 77(1), 109-115. doi:10.4088/JCP.15m10192
Citrome, L., Kando, J., Bliss, C., & Herman, B. (2016). Relationships between the clinical global impressions scale, binge eating days, and the Yale-Brown obsessive compulsive scale modified for binge eating in adults with moderate to severe binge eating disorder in two phase 3 studies. Neuropsychopharmacology, 41(S1), S350-S351.
Citrome, L., Ota, A., Nagamizu, K., Perry, P., Weiller, E., & Baker, R. (2016). The effect of brexpiprazole (OPC-34712) versus aripiprazole in adult patients with acute schizophrenia: An exploratory study. International Journal of Neuropsychopharmacology, 19(Suppl 1), 40-41. doi:10.1097/YIC.0000000000000123
Citrome, L., Ota, A., Nagamizu, K., Perry, P., Weiller, E., & Baker, R. (2016). Treatment of acute schizophrenia in adult patients using either brexpiprazole (OPC-34712) or aripiprazole, an exploratory study. CNS Spectrums, 21(1), 99.
Citrome, L., Ota, A., Nagamizu, K., Perry, P., Weiller, E., & Baker, R. A. (2016). The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia: Results from a randomized, exploratory study. International Clinical Psychopharmacology, 31(4), 192-201. doi:10.1097/YIC.0000000000000123
